Project: Canine Antivascular Drugs Against Cancer

The CADAC’s objective is to test ET-D5, a First-in-Class small molecule with an original anti-vascular and cytostatic mechanism of action, in a clinical trial in dogs with specific and spontaneous cancers. ET-D5 is a new chemical entity (NCE) and our objective is to bring it onto the canine oncology market as soon as possible. CADAC represents the first-in-dog clinical trial, and is susceptible to bring ET-D5 to the market within 1.5 years after its conclusion.

Acronym	CADAC (Reference Number: 9355)
Duration	01/03/2015 - 01/03/2018
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 2

Project partner

Number	Name	Role	Country
20400	Ecrins Therapeutics SAS	Coordinator	France
20401	Animal Oncology and Imaging Center	Partner	Switzerland
20402	Veterinary Referrals Cancer and critical care Centre Limited	Partner	United Kingdom